Description
CJC-1295 with DAC
CJC-1295 with DAC acts by stimulating the growth hormone releasing hormone (GHRH) receptor, promoting sustained activation of growth hormone pathways. The addition of DAC (Drug Affinity Complex) extends the peptide’s half-life, allowing for longer-lasting effects in experimental models. Research has investigated its potential roles in bone metabolism, lean body mass regulation, glucose management, and tissue growth. Preclinical studies indicate that CJC-1295 with DAC can provide more stable growth hormone signaling over time, enhancing outcomes in controlled laboratory settings while maintaining tolerability.




